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We performed a genome-wide association study (GWAS) in 1705 Parkinson’s disease (PD) UK patients and
5175 UK controls, the largest sample size so far for a PD GWAS. Replication was attempted in an additional
cohort of 1039 French PD cases and 1984 controls for the 27 regions showing the strongest evidence of
association (P < 1024). We replicated published associations in the 4q22/SNCA and 17q21/MAPT chromo-
some regions (P < 10210) and found evidence for an additional independent association in 4q22/SNCA. A
detailed analysis of the haplotype structure at 17q21 showed that there are three separate risk groups
within this region. We found weak but consistent evidence of association for common variants located in
three previously published associated regions (4p15/BST1, 4p16/GAK and 1q32/PARK16). We found no sup-
port for the previously reported SNP association in 12q12/LRRK2. We also found an association of the two
SNPs in 4q22/SNCA with the age of onset of the disease.
INTRODUCTION
Parkinson’s disease (PD) is the second most common neurode-
generative disease after Alzheimer’s disease. It affects over 1%
of the elderly population and despite effective symptomatic
therapies is progressive and disabling. The motor phenotype is
characterized by variable severity of bradykinesia, rigidity and
tremor. The age at onset varies, but for the ‘typical sporadic’
patients it is in the seventh decade and beyond. As our popu-
lation ages so the prevalence of PD is increasing. The clinical
definition of the disease is based on the core features listed
above and includes initial responsiveness to levodopa. This
clinical phenotype correlates very highly with the pathological
phenotype of Lewy body neurodegeneration.
Previous genetic studies of familial forms of PD have ident-
ified rare, highly penetrant variants in several chromosome
regions, in particular 4q22/SNCA, 12q12/LRRK2 1p36/Pink1,
1p36/DJ-1 and 6q26/parkin (1,2). However, our knowledge
of the genetic factors underlying the sporadic form of PD
remains poor. The advent of rapid, robust and cost-effective
approaches to a systematic genome-wide association analysis
has enabled appropriately powered large-scale studies to be
undertaken for the first time. Recently, two groups (3,4)
have reported their PD genome-wide association results.
These two studies provided strong evidence of association at
two chromosome regions: 4q22/SNCA and 17q21/MAPT. In
addition, they present suggestive evidence of association for
common variants in three chromosome regions 4p15/BST1,
1q32/PARK16 and 12q12/LRRK2. Edwards et al. (5) have
since confirmed the associations at 4q22/SNCA and 17q21/
MAPT in a meta-analysis totalling 1752 cases and 1745 con-
trols, but they did not find evidence for any other loci associ-
ated with PD. Identification of new associations requires
additional genome-wide association study (GWAS) using
larger sample sizes to provide the required statistical power
to detect subtle effects on PD risk.
RESULTS
To further understand the genetic basis of PD, we undertook a
PD GWAS in the UK population as part of the Wellcome
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Trust Case Control Consortium 2 (WTCCC2). Our initial
sample size consisted of 5667 UK control samples and 2190
UK PD cases passing the aforementioned phenotype criteria
(Supplementary Material, Table S1). UK PD cases were ran-
domly selected from population and hospital-based clinics
with an emphasis on sporadic cases with no family history
for this disease. Half of the cases had been screened for the
known, rare, highly penetrant G2019S mutation (1) in the
LRKK2 gene (see Materials and Methods). We identified 14
G2019S carriers, a frequency consistent with previous
reports of G2019S frequency in UK PD cases. Owing to our
focus on common rather than rare variants, we excluded
these 14 individuals from the GWA scan.
Case samples were genotyped on the Illumina Human660-
Quad platform and control samples were genotyped on the
Illumina 1.2 M Duo platform; the overlap SNP set was used
in this analysis. Following sample quality control (Supplemen-
tary Material, Table S2), our final data set consisted of 1705
cases and 5175 controls. We attempted replication of the top
findings in a French PD case–control collection of 1039
cases and 1984 controls genotyped on the Illumina 610 geno-
typing array (Saad et al., manuscript in preparation).
After removal of 61 568 SNPs that did not pass our quality
filters (see Materials and Methods), 532 616 SNPs remained
for analysis. We used the program SNPTEST (6) to test
each SNP for the association with case–control status using
a score test, analogous to the Cochran–Armitage trend test,
but modified to cope with uncertainty in genotype calls.
Visual inspection of the cluster plots identified a small
number of additional exclusions. An analysis of the distri-
bution of association test statistics after removal of the SNPs
located in two of the established PD associated regions
(4q22/SNCA and 17q21/MAPT) showed an over-dispersion
factor l ¼ 1.039. As the QQ plot (Supplementary Material,
Fig. S1) and the l value do not show widespread departure
from the null model, we deemed it unnecessary to correct
test statistics for inflation.
We found three independent regions associated with PD
with P-values of less than 5 × 1028 (Fig. 1). Two of them
are previously reported findings: 4q22/SNCA (our most associ-
ated SNP rs356220, P ¼ 5.18 × 1029) and 17q21/MAPT
(most associated SNP rs7215239, P ¼ 1.49 × 1028). The
third is in the 7q32 chromosome region, where the top SNP,
rs10447854 (P ¼ 3.11 × 1029), is the only SNP in the
chromosome region showing evidence of association. It is in
low linkage disequilibrium (LD) with other SNPs in the area
and is neighbouring a recombination hotspot (Supplementary
Material, Figure S2). In total, we identified 27 chromosome
regions containing at least one SNP associated at P , 1024
in the UK case–control data (Supplementary Material,
Table S3) and attempted replication at these loci in the
French case–control data set. Among these loci, only the
established associations 4q22/SNCA and 17q21/MAPT suc-
cessfully replicated at P, 1024 (Supplementary Material,
Table S3). The third strong association in our GWAS at
7q32 (rs10447854) showed marginal evidence of association
in the replication set but in the opposite direction to that of
our initial finding. Thorough checks did not find genotyping
errors or allele switches and we therefore assume that in
spite of the convincing statistical evidence in our GWAS,
this result is a false positive.
Next, we examined other reported PD associations for evi-
dence of association in our data. We observed P-values , 0.05
for SNPs in 4p15/BST1 and 4p16/GAK (Table 1). We found no
conclusive support for the published association in the 1q32/
PARK16 chromosome region (4) (Table 1) and, unlike both
previously published PD GWAS of non-familial cases, we
found no evidence of association in the 12q12/LRRK2
chromosome region (Table 1).
To identify further risk variants, which may not be well cor-
related with any single SNP in our data, we used the program
IMPUTE2 (7) to impute an additional 1 200 917 SNPs. To do
so, we exploited data from both the HapMap project (www.
hapmap.org) and additional WTCCC2 genotyping available
for the control collections (see Materials and Methods).
Association analysis of this enriched data set did not yield
any compelling additional signals of association.
Next, we further investigated the signal at the loci showing
strong evidence for association in our data. An association
analysis in the 4q22/SNCA region conditional on the most
associated SNP (rs356220) revealed a second independent
association at rs7687945, which is located 5′ of SNCA. The
Figure 1. Genome-wide association plot. Genome-wide association results for PD at 532, 616 SNPs. Alternating chromosomes are show in shades of blue. Pre-
viously identified loci that also replicate in this study are highlighted in green.
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likelihood ratio test of the one-SNP model compared with
two-SNP model gives a P-value of 2.87 × 1025. This
finding was replicated in the French data (P ¼ 0.00158),
where rs2301134 was used in place of rs7687945 (r2 ¼ 0.98,
calculated in our 58C control data). The two SNPs showing
signals, rs356220 and rs7687945, are in low LD with each
other (r2 ¼ 0.16, calculated in the 58C data), but, interestingly,
the LD is sufficient for the effect of the second SNP to be
masked by that of the first SNP in single-SNP analyses (P ¼
0.131 for rs7687945 in single-SNP analysis). This is an
example of a general phenomenon known in statistics as Simp-
son’s paradox (8,9): association for one variable is seen when
the analysis is stratified by another variable, whereas in a mar-
ginal analysis either no association is observed or it is in the
opposite direction.
To illustrate the pattern of association, we phased the gen-
otypes in this region and estimated the risk and sample fre-
quency of the haplotypes defined by the two SNPs
(Table 2). Viewing the data this way makes clear that the
risk allele at the second SNP rs7687945 is more commonly
found with the protective allele at rs356220 than would be
expected were the SNPs in linkage equilibrium. As a result,
the unconditional risk of the rs7687945 A allele (1.25) relative
to the G allele (1.18) is 1.07 and not significantly different
from 1.0 (Table 2), which explains the lack of marginally
significant association at rs7687945. It is also true that risk
alleles at the first SNP (rs356220) tend to occur with protective
alleles at the second SNP. While this acts to ameliorate the
marginal signal at the first SNP, the combination of haplotype
frequencies and effect sizes is such that there is still a signifi-
cant marginal association.
An important consequence of there being two SNPs affect-
ing disease risk is that the genetic effect at this locus is actu-
ally considerably larger than the marginal analysis suggests.
Table 2 highlights the substantial increase in risk associated
with carrying both of the A alleles: individuals who are homo-
zygote for this allele at both SNPs carry over a 2.5-fold
increase in risk relative to individuals homozygote for the G
alleles.
Having found signals at two SNPs in the association region,
it is natural to ask whether the best statistical model just has
effects for these two SNPs or whether it requires an additional
parameter related to the way in which the SNP alleles combine
onto haplotypes. We assessed this in the phased data and
found no significant improvement in model fit with the
additional, haplotype, parameter (P ¼ 0.1). Although we see
separate signals at two SNPs in our data, this could, in prin-
ciple, arise if disease risk depended on a single, untyped
SNP: for example, if the risk allele at the untyped SNP
occurred with increasing frequencies on the GG, GA, AG
and AA haplotypes in Table 2. To pursue this possibility,
we examined whether any of the SNPs in the 1000 Genomes
data (March 2010 release) in the association region was a
better predictor than either rs356220 or rs7687945, but none
was. In addition, the analysis of the 1000 Genomes data did
not identify non-synonymous SNPs in strong LD (r2. 0.5)
with either rs356220 or rs7687945. It is therefore unlikely
that the effect on PD risk is mediated by a protein coding
change.
A previous study reported additional PD associations in the
5′ region upstream of SNCA (10). However, the LD between
our second signal, rs7687945, and these previously reported
variants is low (r2 ¼ 0.24, 0.26 with rs2736994 and
rs2737026, respectively, calculated in the imputed 58C data)
Table 2. Dissection of risk at the 4q22 locus
Shown in the centre of the table are estimates of odds ratio, 95% confidence
limit (in brackets) and percentage frequency of the four haplotypes defined by
the alleles at rs356220 and rs7687945. In the margins of the table is the risk of
each of the alleles obtained by averaging the odds ratio of two haplotypes on
which the allele can be found, weighting by the sample frequency. For example,
the risk of carrying the G allele at rs356220 unconditional on the allele carried
at rs7687945 is 1.11 (given in the top right) and is calculated as (1 × 20.8 +
1.16 × 41.9)/(20.8 + 41.9). By comparing the unconditional risks of the two
alleles at each SNP, we recover the odds ratio estimated from a single SNP
analysis.
Table 1. Association results at previously reported loci
Chr Locus SNP Position Risk allele RAFa P-value ORb (95% CI)
Cases Controls
1q32 PARK16 rs823128 203980001 A 0.975 0.969 0.059 1.25 (0.99–1.57)
4p16 GAK rs1564282 842313 A 0.103 0.089 0.016 1.17 (1.03–1.34)
4p15 BST1 rs4698412 15346446 A 0.567 0.547 0.046 1.08 (1.00–1.17)
4q22 SNCA rs2736990 90897564 G 0.501 0.449 1.36 × 1027 1.23 (1.14–1.33)
12q12 LRRK2 rs1994090 38714828 C 0.234 0.225 0.338 1.05 (0.95–1.15)
17q21 MAPT rs393152 41074926 A 0.803 0.757 4.75 × 1028 1.31 (1.19–1.44)
Association results from the discovery data set for loci which have been associated with sporadic PD in previous genome-wide association studies.
aRisk allele frequency.
bOdds ratio shown for the risk allele.
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and these previous associations were only found in female and
young onset cases. Further analysis is required to determine
whether these observations represent an independent associ-
ation signal.
The 17q21 hit region falls on a known polymorphic 900 kb
inversion. The two forms of the inversion, often termed H1
and H2, vary in frequency globally, with the minor H2 haplo-
type found almost exclusively in Southwest Asian and Euro-
pean populations, at a frequency of 5–30% (11–13). There
is some evidence that H2 is under selection in Europe,
where it has been linked to higher recombination rate and
greater fertility (12). Suggestive associations of the region
with Crohn’s disease and type 1 diabetes have recently been
reported (14). There is very little evidence of recombination
between the two orientations of the inversion, but within
these, H1 shows relatively normal recombination and variation
patterns, whereas there is very little variation within the H2
haplotype (15). Analyses of the age of the inversion event
and its history have led to differing conclusions
(11,12,16,17). The inversion encompasses several genes, and
the most associated SNP in our GWAS, rs7215239, is
located in the promoter region of the MAPT gene. The
minor allele at rs7215239 (G) is protective for PD and is in
LD with multiple SNPs over a large region tagging the H2
and H1 haplotypes, an association result consistent with a pre-
vious study (18). Within the H1 haplotype, there is genetic
diversity, and many sub-haplotypes have been determined
(12). To date, results for associations of these sub-haplotypes
with PD have shown contradictory findings (19), with one
study showing distinct H1 sub-haplotypes associated with
PD and supranuclear palsy (18,19) and another study indicat-
ing that the PD association at the MAPT gene is not due to the
different sub-haplotypes of H1 but explained by the H1/H2
inversion (18). However, it has been demonstrated that a
subset of H1 haplotypes (referred to as H1c) is associated
with increased MAPT expression (20).
In order to further investigate the association at this locus,
we used a recently published software package, GENECLUS-
TER (21), to find evidence for causal mutation(s). GEN-
ECLUSTER looks for evidence of potential additional
association signals by examining the clustering of case and
control haplotypes at the tips of a genealogical tree estimated
from reference-panel data (here HapMap CEU) at a fine grid
of locations. Differential clustering under a particular branch
of the tree suggests the possibility of a mutation on that
branch which affects disease risk. GENECLUSTER assesses
evidence for association in a Bayesian framework, and inves-
tigates models where there is one, and separately two, disease-
predisposing mutation in the region.
In the 17q21 hit region, the strongest GENECLUSTER evi-
dence for association results in a log10(Bayes factor) of 6.22
under the two-mutation model. At the same position, the one-
mutation model log10(Bayes factor) is much smaller at 5.23,
which strongly suggests that more than one variant is needed
to explain the association.
The most likely two-mutation model identified three haplo-
type risk backgrounds, corresponding to H2 and two subsets of
H1 (Fig. 2). These three groups are well tagged by four SNPs
(rs9303521, rs11079711, rs12938476, rs1880756) with the
TGCC haplotype defining H2, and GATT, TGTC or TGTT
haplotypes defining a subset of H1 haplotypes partitioning it
into two risk groups. We phased the study genotypes across
the region and labelled individuals according to the alleles
carried at the four tagging SNPs. These data supported a
three-group model, with H1 haplotypes separated into two
risk groups, over a two-group model separating just H1 and
H2 (likelihood ratio test P ¼ 0.003). Relative to the risk of
the H2 haplotype, we estimate one subset of H1 haplotypes
(Fig. 2, coloured red) to have a risk of 1.18 (95% CI 1.07–
1.30), and the other set of H1 haplotypes (Fig. 2, coloured
blue) to have a risk of 1.36 (95% CI 1.23–1.50). For replica-
tion, we tested the same three-group model defined by the
sets of haplotypes at these SNPs in the French data and
Figure 2. Haplotype tagging of three risk groups identified at the 17q21 locus.
The tree shown represents the estimated ancestral relationship between
HapMap 2 chromosomes at position 41.19 Mb on chromosome 17 (note that
the tree is not scaled relative to time). GENECLUSTER analysis identified
three risk groups defined by the braches subtending the blue, green and red
circles which represent putative mutation events. Shown on the left are haplo-
types delineated by four SNPs chosen to tag the three risk groups. Each
chromosome carrying the allele listed by the rsID at the top the figure is
coloured according to the haplotype group to which they are assigned. The
green haplotypes demark the two orientations labelled H1 and H2, of the
large inversion polymorphism encompassing the 17q21 region (see text).
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found it significant at P ¼ 0.026 (OR ¼ 1.18, 95% CI 1.03–
1.35 for the low-risk H1 haplotype and OR ¼ 1.37, 95%
CI 1.19–1.58 for the high risk H1 haplotype).
We also investigated whether the two main associations at
SNCA and MAPT showed evidence of interaction, i.e. a depar-
ture from the simple model in which the risks for the main
SNP at each locus combine multiplicatively. Using a one
degree-of-freedom case only test for genotype correlations
(22) between the MAPT SNP and each of the two SNCA
SNPs, we found no evidence of interaction (P . 0.05).
A further association study was carried out in the PD data,
treating the age of onset as a quantitative trait. No SNP passed
a stringent significance threshold (P ¼ 1027). However,
motivated by the higher prior belief of a potential association
with the age of onset for PD-associated loci, we used a less
stringent significance threshold for the PD-associated SNPs
in the MAPT and SNCA chromosome regions. This analysis
identified an age at onset association for both PD-associated
SNPs in SNCA. As with the case–control analysis, the evi-
dence at these SNPs is the strongest when they are both
included in the model: F-test of the two-SNP model gives a
P-value of 6.37 × 1024 compared with either rs7687945
(P ¼ 0.0049) or rs356220 (P ¼ 0.189) when tested separately.
The direction of risk at these SNPs is the same as in the case–
control analysis (Table 3). Individuals carrying homozygote A
alleles at both SNPs have an average 5.48 year earlier onset of
PD than those carrying homozygote G alleles at both SNPs.
The association of the pair of SNPs with the age of onset
was replicated in the French data (P ¼ 0.02, with rs2301134
used as a proxy for rs7687945). However, while the direction
of effects is the same, the individual effects and marginal sig-
nificance of the two SNPs differ somewhat in the discovery
and replication data sets (Table 3), so we would recommend
some caution pending further replication.
DISCUSSION
We undertook a GWAS for PD in 1705 cases and 5175 con-
trols. We found strong support for previously reported associ-
ations at 4q22 and 17q21, and support at P , 0.05 at 4p15 and
4p16. An earlier reported association around LRRK2 did not
replicate in our study.
We undertook additional analyses at the two major GWAS
loci, 4q22/SNCA and 17q21/MAPT, and in each case uncov-
ered additional signals. At 4q22/SNCA, association analysis
conditioned on the top SNP revealed a second independent
signal which was masked in single-SNP analyses. The pres-
ence of the additional signal substantially increases the size
of the genetic effect at the locus, with each additional copy
of the risk allele at both loci increasing disease risk by a
factor of 1.65. SNCA is a likely candidate in this region:
SNCA is a major component of Lewy bodies, the abnormal
inclusions in the brain which are important in PD pathology,
and previous studies have linked PD risk with SNCA over-
expression caused by triplications of this gene (2). Our
results suggest that SNCA risk alleles for PD may well also
be associated with earlier disease onset. Previous reports
have associated rare copy number variants in SNCA with the
age of onset, whereby duplications are associated with late
onset and triplications associated with early onset (23).
Together these observations suggest a key role for SNCA in
PD susceptibility and progression, which is potentially directly
related to gene expression and therefore a-synuclein concen-
trations (2).
We found that there are at least three haplotype groups at
17q21 with differing risk. Further characterizing these haplo-
types and determining the mechanisms behind the several
associations reported at the 17q21 locus is an important pri-
ority for further work. While MAPT is a strong PD candidate
gene in 17q21 and MAPT has differential expression in the H1
and H2 haplotypes, with higher expression in H1 compared
with H2 (20,24), the PD association could well involve
another gene. In particular, the H1/H2 genotype is weakly
associated with type 1 diabetes and Crohn’s disease risk (14)
which indicates that variants on this large haplotype may
affect multiple pathways.
For the P-value threshold of 1024 that we used to select loci
for replication, our sample size provides 93% power to detect
an allele with a minor allele frequency (MAF) of 20% and an
effect size of 1.3. Given the good genome coverage of the Illu-
mina Human660-Quad platform that was used in this study,
the absence of additional replicated associations suggests
that 4q22/SNCA and 17q21/MAPT may be the only common
variants with effects of this magnitude on PD risk in the UK
population. However, and in addition to the well-documented
contribution of highly penetrant rare variants for PD risk, our
results cannot rule out the presence of a significant number of
common associations but with smaller odds ratio. Future
pooling of existing case–control studies into large
meta-analyses is required to increase the statistical power to
detect weaker associations and improve our understanding of
the genetic architecture of PD.
MATERIALS AND METHODS
Case and control samples
Prior to any exclusion, the full data set comprised 2190 indi-
viduals with idiopathic PD, and 5667 population controls.
Known familial cases and individuals with known Mendelian
mutations (including LRRK2 mutations) were excluded. The
samples were collected through five UK-wide centres (Sup-
plementary Material, Table S1). Case samples collected in
London and Cardiff were screened for the previously reported
highly penetrant and rare G0219S mutation in the LRKK2
gene. The 14 G0219S carriers that we identified were excluded
from the GWA study. The control data set was that of the pre-
viously described WTCCC2 study (25)—totalling 2930
samples from the 1958 Birth Cohort (58C) and 2737
samples from the UK Blood Services Controls (NBS).
Phenotype definition
All case subjects met the UK Brain Bank Clinical Criteria for
PD (26). Of the 1705 samples that progressed through to
analysis, age of onset was available for 1439 samples. The
mean age of disease onset, as defined by reported age of
first motor symptom, was 65.8, with the youngest at age 29
years and the oldest at age 105 years. The male-to-female
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ratio in this data was 2.7:1. Samples were excluded if they had
previously been shown to have likely causative mutation in a
known PD gene. All the Brain Bank cases had pathologically
proven PD Braak stages (5,6).
DNA sample preparation
Genomic DNA for all cases was shipped to the Wellcome
Trust Sanger Institute (WTSI), Cambridge. DNA concen-
trations were quantified using a PicoGreen assay (Invitrogen)
and an aliquot assayed by agarose gel electrophoresis. A
DNA sample was considered to pass quality control if the orig-
inal DNA concentration was ≥50 ng/ml and the DNA was not
degraded. In order to track sample identity, 30 SNPs, includ-
ing sex chromosome markers, were typed on the Sequenom
platform prior to entry to the whole genome genotyping pipe-
line.
Genotyping methodology and quality control
Genotyping of the samples was carried out at the WTSI on the
Illumina BeadArray platform. Cases were genotyped on the
Illumina Human660-Quad array and the controls were geno-
typed on the Illumina 1.2 M Duo array. Normalized probe
intensities were exported using the BeadStudio program and
genotypes called separately in the 58C, NBS and PD data
sets using the program Illuminus (27). For the purposes of
quality control, SNPs were excluded from analysis if, in any
of the data sets (58C, NBS or PD), they had a MAF less
than 0.01%, a significant departure from Hardy Weinberg
equilibrium (P , 10220) or a significant association with the
plate on which the samples were assayed (P , 1026). We
also excluded SNPs for which the observed statistical
(Fisher) information about the allele frequency was less than
98% of the information contained in a hypothetical sample
of the same size and expected MAF but with no missing
data. An additional 39 SNPs were removed following visual
inspection of cluster plots. In total, 61 636 SNPs were
removed from the overlap set on the two genotyping chips,
leaving 532 588 for association analysis. Sample exclusions
were based on four genome-wide summary statistics of the
genotyping data designed to be sensitive to possibly sources
of heterogeneity: fraction of missing genotypes, autosomal
heterozygosity, a measure of African and Asian ancestry
(defined by a principal component analysis of the HapMap 2
data) and the average difference in the probe intensities
across SNPs. By modelling the distribution of each of these
summaries as a mixture, we inferred outlying individuals
and excluded them from analysis. Furthermore, we exclude
one of each pair of individuals showing greater than 5% iden-
tity by descent by inferring chromosomal sharing at a genome-
wide subset of 11 547 SNPs. To reduce the risk of errors
through sample swaps, we also removed samples for which
the reported gender and genetically determined gender were
discordant, or where Illumina array-based genotypes disagreed
with more than 10% of the Sequenom genotypes which were
typed as part of sample preparation described above. After
sample quality control, 1705 cases and 5175 controls sample
remained for analysis (Supplementary Material, Table S2).
Imputation and haplotype phasing
Haplotype phasing and imputation was performed using
IMPUTE2 (7), which adopts a two-stage approach using
both haploid and diploid reference panels. For the haploid
reference panel, we used HapMap2 and HapMap3 SNP data
for the 120 non-related CEU trios (see www.hapmap.org),
and for the diploid reference we used 58C and NBS control
data, merging genotypes from the Illumina 1.2 M Duo chip
and Affymetrix Genome Wide Human SNP array 6.0. Prior
to analysis with IMPUTE2, we applied standard quality
control filters akin to those described above. To further
protect against potential errors misleading the imputation
and phasing, we checked that each genotype conformed to
local patterns of LD in HapMap by employing a leave-one-out
imputation strategy. Specifically, we ran IMPUTE (7) on each
of the study samples in turn, both cases and controls,
re-imputing known genotypes. Control individuals for which
the imputed genotypes were more than 4.5% discordant with
the original genotype were removed. The same rule was
applied to case individuals with a discordance threshold of
6%. SNPs for which IMPUTE was confident of the imputation
call but the genotyped data were discordant (and therefore
indicative of genotyping error) were also removed if the differ-
ence between measure of information and error rate was
greater than 0.05.
Statistical analysis
Genome-wide case–control analysis was performed using fre-
quentist tests, under a missing data logistic regression model,
as implemented in the program SNPTEST (6). Unless other-
wise stated, we assumed a multiplicative model for allelic
risk by encoding the genotypes at each SNP as a discrete
explanatory variable with an indicator of case status as the
binary response. We note that an analogous analysis using
the Cochran–Armitage trend test in PLINK (29), ignoring
the uncertainty in genotype calls, gave very similar results
(data not shown). To look for secondary independent signals
Table 3. Evidence of association at the 4q22 locus with age of onset
SNP rs356220 rs7687945a
Position 90860363 90983722
Risk allele A A
Discovery sample
Risk allele frequency
(cases, controls)
0.41, 0.36 0.53, 0.51
F-test two-SNP P-value 6.62 × 1024
Estimate effect in years 1.17 (0.3–2.0) 1.57 (0.71–2.42)
Replication sample
F-test two-SNP P-value 0.0204
Estimated effect in years 1.80 (0.51–3.09) 0.80 (0.47–2.06)
Association analysis at two SNPs in the 4q22/SNCA region in the original
discovery data and in the French data used for replication. Analysis was
performed using a linear model with age of onset as the response variable and
the two SNPs as predictors. Note that we report the estimated effect of the A
allele at the two SNPs in terms of the reduction in the time to onset of PD.
aIn the replication French data rs2301134 was used as a proxy for rs7687945
(r2 ¼ 0.98).
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within associated loci, we included the SNP with the lowest
trend test P-value in the logistic regression model as a discrete
covariate using PLINK (28). Likelihood ratio tests were used
to compare one-SNP to two-SNP models in order to identify
SNPs within the loci with independent effects on risk. For
the analysis of haplotypes in the 4q22 and 17q21 regions,
we employed logistic regression models to estimate the risk
associated with carrying each of the haplotypes or where rel-
evant set of haplotypes, by including a set of indicator vari-
ables denoting the haplotypes carried by each study
individual. To formally compare the two-group haplotype
model to the three-group model at 17q21, we re-encoded hap-
lotypes to form a nested model and tested the need for an indi-
cator of membership of the two risk groups within the H1
background. These analyses were carried out in the statistical
package R.
Age of onset analysis was carried out by treating it as a con-
tinuous quantitave response in a linear regression model.
Genome-wide analysis was performed using frequentist tests
in SNPTEST calculated using missing data likelihoods. To
look in detail at the combined effect of the two SNPs in
4q22, we reanalysed the data in R. Meta analysis results for
both age of onset and case–control analysis were obtained
assuming a standard fixed effects model to combine estimates
of the odds ratio and standard errors across studies.
It has become standard practice in GWAS to refer to the
odds ratio associated with a particular allele or haplotype,
which we estimate to be the eb, where b is the maximum like-
lihood estimate of the coefficient describing the effect of each
predictor on the response in the assumed model. We note
however that, as is of true this study and many others,
where the controls are taken at random from the population
without reference to case status, b is actually the log of the
relative risk and not the log of the odds ratio.
Replication strategy
For in silico replication, we exchanged genotype data with a
study carried out in the French population using a similar
study design. The French data set consisted of a total of
1039 cases and 1984 controls (see Saad et al., manuscript in
preparation). These samples were typed on the Illumina 610
platform, which has an overlap of 473 892 SNPs with our
study. Selecting only from the subset of SNPs which passed
quality control in both studies, association test data for 100
SNPs were exchanged. This SNP replication list included
the 55 top hit SNPs from our study (Supplementary Material,
Table S3), 20 randomly selected control SNPs and 25 SNPs
from the two most recently published PD GWAS studies
(3,4). Owing to the significant level of population structure
in the French GWA scan, the association test included covari-
ates for population structure computed from a principal com-
ponent analysis (29).
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